PFIZER

Drug Name	Phase	Indication	Designations	Patent
FSME-IMMUN NEW 0.25 ml	Phase 3	Tick-borne Encephalitis	-	-
Insulin Lispro	Phase 3	Diabetes Mellitus	-	-
Cyclosporine A	Phase 3	Renal Transplantation	-	-
Ibuprofen 600 mg ER	Phase 3	Pain	-	-
cefuroxime plus erythromycin	Phase 3	Pneumonia	-	-
PF-05280014	Phase 3	Metastatic Breast Cancer	-	-
Quillivant Oral Suspension XR	Phase 3	Attention Deficit Hyperactivity Disorder	-	-
Prevenar 13™	Phase 3	Infections, Meningococcal	-	-
Desvenlafaxine Succinate	Phase 3	Major Depressive Disorder	-	-
Enzalutamide	Phase 3	Breast Cancer	-	-
CP 690,550 5 mg	Phase 3	Psoriasis	-	-
Voriconazole	Phase 3	Neutropenia	-	-
indobufen	Phase 3	Atrial Fibrillation	-	-
Adalimumab	Phase 3	Rheumatoid Arthritis	-	-
PF-04965842 200 mg	Phase 3	Dermatitis	-	-
Methotrexate	Phase 3	Arthritis, Rheumatoid	-	-
desvenlafaxine 50 mg	Phase 3	Depressive Disorder, Major	-	-
Isovorin	Phase 3	Gastric Cancer	-	-
Nirmatrelvir	Phase 3	COVID-19	-	-
Doripenem	Phase 3	Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis	-	-
Midazolam	Phase 3	Sedation	-	-
Artemether-lumefantrine	Phase 3	Malaria, Falciparum	-	-
Crizotinib	Phase 3	Non Small Cell Lung Cancer	-	-
Rapamune	Phase 3	Renal Allograft Recipients	-	-
Effexor XR	Phase 3	Depression	-	-
Fesoterodine PR 4 mg	Phase 3	Urinary Bladder, Neurogenic	-	-
cisplatin	Phase 3	Carcinoma, Non-Small-Cell Lung (NSCLC)	-	-
desipramine	Phase 3	Depression	-	-
procarbazine hydrochloride	Phase 3	Brain and Central Nervous System Tumors	-	-
Abrocitinib 100 mg	Phase 3	Atopic Dermatitis	-	-
desvenlafaxine succinate sustained release	Phase 3	Vasomotor Symptoms	-	-
Anidulafungin, VER002	Phase 3	Aspergillosis	-	-
treatment	Phase 3	Non Squamous Lung Cancer	-	-
Tofacitinib	Phase 3	Rheumatoid Arthritis	-	-
fluorouracil	Phase 3	Colorectal Cancer	-	-
Crisaborole 2%	Phase 3	Atopic Dermatitis	-	-
Duloxetine 60 mg/day	Phase 3	Depressive Disorder, Major	-	-
Etrasimod	Phase 3	Alopecia Areata	-	-
Elranatamab	Phase 3	Multiple Myeloma	-	-
Fenofibrate	Phase 3	Hyperlipidemia	-	-
Azithromycin SR	Phase 3	Acute Bronchitis	-	-
Disease-modifying antirheumatic drug	Phase 3	Arthritis, Rheumatoid	-	-
Ritlecitinib 100 mg	Phase 3	Vitiligo	-	-
20vPnC	Phase 3	Pneumococcal Disease	-	-
Genotonorm	Phase 3	Growth Disorders	-	-
Varenicline tartrate	Phase 3	Smoking Cessation	-	-
Irinotecan	Phase 3	Glioma	-	-
pegaptanib sodium	Phase 3	Macular Degeneration	-	-
tanezumab 5 mg	Phase 3	Arthritis	-	-
Tanezumab 2.5 mg	Phase 3	Osteoarthritis, Knee	-	-
rLP2086 vaccine	Phase 3	Meningitis, Meningococcal	-	-
Apixaban	Phase 3	Atrial Fibrillation	-	-
Azithromycin plus Chloroquine	Phase 3	Malaria	-	-
Talazoparib	Phase 3	Prostate Cancer	-	-
atorvastatin	Phase 3	Hypercholesterolemia, Familial	-	-
Fx-1006A	Phase 3	Familial Amyloid Polyneuropathy	-	-
Sulfadoxine-Pyrimethamine/Chloroquine	Phase 3	PLASMODIUM FALCIPARUM MALARIA	-	-
Mefloquine	Phase 3	Malaria, Falciparum	-	-
CP 690,550	Phase 3	Rheumatoid Arthritis	-	-
PN-152,243)/PN-196,444	Phase 3	Sarcoma	-	-
Physician's-Choice	Phase 3	Breast Neoplasms	-	-
Bazedoxifene Acetate	Phase 3	Osteoporosis	-	-
PF-04965842 100 mg	Phase 3	Dermatitis, Atopic	-	-
gemcitabine hydrochloride	Phase 3	Lung Cancer	-	-
Sigvotatug Vedotin	Phase 3	Non-Small Cell Lung Cancer	-	-
Epogen Amgen	Phase 3	Chronic Renal Failure	-	-
desvenlafaxine SR	Phase 3	Depression	-	-
Standard of Care FIX Replacement therapy	Phase 3	Hemophilia B	-	-
PVC (daily for 21 days, 7 days off)	Phase 3	Atrophic Vaginitis	-	-
Dexmedetomidine HCL Injection	Phase 3	Awake Fiberoptic Intubation	-	-
Bazedoxifene/Conjugated Estrogen	Phase 3	Vaginal Atrophy	-	-
desvenlafaxine succinate sustained release tablets	Phase 3	Major Depressive Disorder	-	-
Cyclosporine	Phase 3	Kidney Transplant	-	-
Amphotericin B	Phase 3	Mycoses	-	-
Pegvisomant	Phase 3	Acromegaly	-	-
Ceftaroline	Phase 3	Community-Acquired Bacterial Pneumonia	-	-
MenACWY-TT	Phase 3	Meningococcal ACWY Disease	-	-
Tamoxifen	Phase 3	Breast Neoplasms	-	-
PF-06741086	Phase 3	Hemophilia A	-	-
Clostridium difficile vaccine	Phase 3	Clostridium Difficile Associated Disease	-	-
DVS-SR 50 mg	Phase 3	Major Depressive Disorder	-	-
Varenicline	Phase 3	Smoking	-	-
RSVpreF Vaccine	Phase 3	Respiratory Syncytial Virus	-	-
Levofloxacin	Phase 3	Community-Acquired Infections	-	-
daunorubicin + cytarabine	Phase 3	Leukemia, Myeloid, Acute	-	-
Dimebon	Phase 3	Alzheimer's Disease	-	-
PF-06801591	Phase 3	Advanced Malignancies	-	-
fulvestrant	Phase 3	Uterine Neoplasms	-	-
Desvenlafaxine Sustained Release	Phase 3	Fibromyalgia	-	-
Bacillus Calmette-Guerin	Phase 3	Non-muscle Invasive Bladder Cancer	-	-
Pemetrexed	Phase 3	Carcinoma, Non-Small-Cell Lung	-	-
IBU BID	Phase 3	Pain	-	-
PF-07248144	Phase 3	Breast Cancer	-	-
PF-06838435/ fidanacogene elaparvovec	Phase 3	Hemophilia B	-	-
gemtuzumab ozogamicin	Phase 3	Leukemia	-	-
13vPnC + TIV	Phase 3	Pneumococcal Infections	-	-
Zyvox® / Linezolid	Phase 3	Bacterial Infections	-	-
CP-690,550 (tofacitinib)	Phase 3	Juvenile Idiopathic Arthritis	-	-
PF-02341066	Phase 3	Carcinoma, Non-Small-Cell Lung	-	-
Antibiotic	Phase 3	Pneumonia, Pneumococcal	-	-
Sunitinib + Capecitabine	Phase 3	Breast Neoplasms	-	-
Axitinib (AG-013736)	Phase 3	Hepatocellular Carcinoma	-	-
Osivelotor	Phase 3	Sickle Cell Disease	-	-
Imatinib	Phase 3	Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive	-	-
DIC075V (intravenous diclofenac sodium)	Phase 3	Pain, Postoperative	-	-
PhXA41	Phase 3	Glaucoma	-	-
Interferon Alfa	Phase 3	Carcinoma, Renal Cell	-	-
13-valent Pneumoccocal Conjugate Vaccine	Phase 3	Pneumococcal Conjugate Vaccine	-	-
PF-08634404	Phase 3	Carcinoma, Hepatocellular	-	-
Fragmin/ Dalteparin Sodium	Phase 3	Diabetic Foot Ulcer	-	-
Temsirolimus (CCI-779)	Phase 3	Advanced Renal Cell Carcinoma	-	-
Glasdegib	Phase 3	Acute Myeloid Leukemia	-	-
Rimegepant 25 MG	Phase 3	Migraine	-	-
chemotherapy	Phase 3	Leukemia	-	-
(PN-152,243)/ PN-196,444	Phase 3	Non-Hodgkin Lymphoma	-	-
fluoxetine	Phase 3	Major Depressive Disorder	-	-
MERREM I.V. 2g as a 3 hour infusion every 8 hours	Phase 3	Pneumonia	-	-
PF-07055480 (giroctocogene fitelparovec): Recombinant AAV2/6 Human Factor VIII Gene Therapy	Phase 3	Hemophilia A	-	-
Ertapenem	Phase 3	Bacterial Infections	-	-
Inclacumab	Phase 3	Sickle Cell Disease	-	-
Daratumumab	Phase 3	Multiple Myeloma	-	-
Dazukibart	Phase 3	Dermatomyositis	-	-
Docetaxel	Phase 3	Carcinoma, Non-Small-Cell Lung	-	-
Azithromycin microspheres 2.0 single dose	Phase 3	Community-Acquired Pneumonia	-	-
Mevrometostat	Phase 3	Metastatic Castration Sensitive Prostate Cancer (mCSPC)	-	-
Crisaborole Ointment	Phase 3	Atopic Dermatitis	-	-
Vanquix Auto-Injector (Diazepam Injection)	Phase 3	Seizures	-	-
Dexmedetomidine hydrochloride	Phase 3	Sedation	-	-
Rimegepant/BHV3000	Phase 3	Pediatric Migraine	-	-
PF-06438179	Phase 3	Rheumatoid Arthritis	-	-
Fentanyl	Phase 3	Anesthesia	-	-
Irinotecan + 5 FU + folinic acid	Phase 3	Colorectal Neoplasms	-	-
NSAID	Phase 3	Chronic Pain	-	-
Ritlecitinib lower dose	Phase 3	Severe Alopecia Areata	-	-
Epogen (Amgen)	Phase 3	Chronic Kidney Disease	-	-
PPSV23	Phase 3	Pneumococcal Disease	-	-
"Investigational"Auto-injector (sumatriptan succinate)	Phase 3	Migraine	-	-
VLA15	Phase 3	Lyme Borreliosis	-	-
Lenalidomide	Phase 3	Multiple Myeloma	-	-
Bococizumab (PF-04950615; RN316)	Phase 3	Hyperlipidemia	-	-
23-valent Pneumococcal Polysaccharide Vaccine	Phase 3	Pneumococcal Vaccines	-	-
BeneFIX	Phase 3	Hemophilia B	-	-
Background NSAID	Phase 3	Spondylitis, Ankylosing	-	-
VFENDÂ® I.V., Oral	Phase 3	Candidiasis	-	-
DVS SR	Phase 3	Depressive Disorder, Major	-	-
PF-06821497	Phase 3	Metastatic Castrate Resistant Prostate Cancer (mCRPC)	-	-
Ribociclib	Phase 3	Breast Cancer	-	-
CP-945,598	Phase 3	Obesity	-	-
Ibuprofen 400 mg caplet	Phase 3	Patient Compliance	-	-
cabergoline	Phase 3	Restless Legs Syndrome	-	-
voriconazole (Vfend)	Phase 3	Candidiasis	-	-
Acetaminophen	Phase 3	Pain	-	-
Ceftriaxone sodium	Phase 3	Intra-abdominal Infections	-	-
Bazedoxifene Acetate (TSE-424)	Phase 3	Osteoporosis	-	-
Bococizumab 150mg	Phase 3	Hyperlipidemia	-	-
topotecan	Phase 3	Cervical Cancer	-	-
PF-08046054	Phase 3	Non-small Cell Carcinoma	-	-
Dupilumab	Phase 3	Dermatitis	-	-
CP-690, 550	Phase 3	Psoriasis	-	-
Rimegepant 75mg Orally Disintegrating Tablets (ODT)	Phase 3	Acute Migraine	-	-
CAZ-AVI	Phase 3	Complicated Intra-Abdominal Infection	-	-
Milnacipran	Phase 3	Depression	-	-
naproxen	Phase 3	Osteoarthritis	-	-
Ibuprofen 250 mg	Phase 3	Post-surgical Pain Following Extraction of Molar Teeth	-	-
Temsirolimus	Phase 3	Renal Cell Carcinoma	-	-
Etoposide + cisplatin	Phase 3	Small Cell Lung Carcinoma	-	-
20-valent pneumococcal conjugate vaccine (20vPnC)	Phase 3	Pneumococcal Disease	-	-
Unfractionated Heparin (UFH)	Phase 3	Deep Vein Thrombosis	-	-
tolterodine tartrate	Phase 3	Overactive Bladder	-	-
bazedoxifene BZA-20	Phase 3	Postmenopause	-	-
rimegepant 75 mg ODT	Phase 3	Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps	-	-
Rapamune®	Phase 3	Kidney Disease	-	-
Pertuzumab	Phase 3	HER2 Positive Breast Cancer	-	-
Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine	Phase 3	Alopecia Areata	-	-
23-valent Pneumococcal Polysaccharide Vaccine (23vPS)	Phase 3	HIV Infections	-	-
Anidulafungin	Phase 3	Neutropenia	-	-
adenosine	Phase 3	Coronary Artery Disease	-	-
Dexamethasone	Phase 3	Multiple Myeloma	-	-
Varenicline Tartarate	Phase 3	Smoking Cessation	-	-
Abrocitinib 200 mg	Phase 3	Dermatitis, Atopic	-	-
Placebp	Phase 3	Respiratory Syncytial Virus	-	-
Treatment with Genotropin in different dosages	Phase 3	Growth Disorder	-	-
prinomastat	Phase 3	Brain and Central Nervous System Tumors	-	-
MEK162	Phase 3	Metastatic Colorectal Cancer	-	-
Tofacitinib 5 mg BID	Phase 3	Psoriatic Arthritis	-	-
Abrocitinib	Phase 3	Atopic Dermatitis	-	-
5 fluorouracil	Phase 3	Metastatic Colorectal Cancer	-	-
LGX818	Phase 3	Solid Tumors Harboring a BRAF V600 Mutation	-	-
vemurafenib	Phase 3	Melanoma	-	-
Genotonorm (Somatropin)	Phase 3	Fetal Growth Retardation	-	-
Xyntha	Phase 3	Hemophilia A	-	-
Zavegepant (BHV-3500)	Phase 3	Acute Migraine	-	-
Desvenlafaxine succinate sustained release 50 mg	Phase 3	Major Depressive Disorder	-	-
RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE	Phase 3	Respiratory Syncytial Virus (RSV)	-	-
SU011248	Phase 3	Gastrointestinal Stromal Tumors	-	-
Pantoprazole for approximately 9 weeks	Phase 3	Gastroesophageal Reflux	-	-
pantoprazole sodium enteric-coated spheroid	Phase 3	Gastroesophageal Reflux	-	-
Seasonal Inactivated Influenza Vaccine	Phase 3	Respiratory Syncytial Virus	-	-
Investigator's choice	Phase 3	Lymphoma	-	-
azithromycin (Zithromax)	Phase 3	Pharyngitis	-	-
IV Diclofenac	Phase 3	Postoperative Pain	-	-
Morphine	Phase 3	Sedation	-	-
oxaliplatin	Phase 3	Colorectal Neoplasms	-	-
Piperacillin/Tazobactam (Tazocin)	Phase 3	Hematologic Neoplasms	-	-
effervescent ibuprofen tablets	Phase 3	Pain	-	-
CP690,550	Phase 3	Ulcerative Colitis	-	-
Fesoterodine PR 8 mg	Phase 3	Urinary Bladder, Neurogenic	-	-
mycophenolate mofetil	Phase 3	Graft vs Host Disease	-	-
azithromycin sustained release	Phase 3	Pneumonia	-	-
FOLFIRI regimen	Phase 3	Colorectal Cancer	-	-
ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride Extended Release)	Phase 3	Osteoarthritis	-	-
leucovorin	Phase 3	Colorectal Carcinoma	-	-
azithromycin SR (Zithromax; compound: CP-62,993)	Phase 3	Maxillary Sinusitis	-	-
clarithromycin extended release (ER)	Phase 3	Pneumonia	-	-
Xiapex	Phase 3	Dupuytren's Contracture	-	-
MTZ	Phase 3	Complicated Intra-abdominal Infection	-	-
anastrozole	Phase 3	Breast Neoplasms	-	-
Standard of Care	Phase 3	Macular Edema Associated With Diabetes Mellitus	-	-
vaccine-13vPnC	Phase 3	Pneumococcal Infections	-	-
PF-04965842	Phase 3	Atopic Dermatitis	-	-
ATM-AVI	Phase 3	Complicated Intra-Abdominal Infections, cIAIs	-	-
Recombinant Coagulation Factor IX (BeneFIX)	Phase 3	Hemophilia B	-	-
Ibuprofen 250 mg / Acetaminophen 500 mg	Phase 3	Fever	-	-
Celecoxib	Phase 3	Schizophrenia	-	-
Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl	Phase 3	Encephalitis, Tick-Borne	-	-
Xalacom	Phase 3	Glaucoma, Open-Angle	-	-
Amlodipine	Phase 3	Hypertension	-	-
Topical IBU twice daily	Phase 3	Ankle Injuries	-	-
PLD	Phase 3	Ovarian Cancer	-	-
Lorlatinib	Phase 3	Carcinoma, Non-Small-Cell Lung	-	-
Ibuprofen 600 mg Immediate Release/Extended Release Caplet	Phase 3	Analgesia	-	-
Clostridium difficile	Phase 3	Clostridium Difficile Associated Disease	-	-
PD 0332334	Phase 3	Generalized Anxiety Disorder	-	-
Taxotere®	Phase 3	Early Breast Cancer	-	-
Ramipril and hydrochlorothiazide	Phase 3	Hypertension	-	-
PD-0332991	Phase 3	Neoplasms	-	-
UFT	Phase 3	Colon Cancer	-	-
PF-07275315 dose 1	Phase 3	Moderate to Severe Chronic Obstructive Pulmonary Disease	-	-
PF-08653944	Phase 3	Obesity	-	-
5-FU	Phase 3	Neoplasms	-	-
Leuprolide Open Label	Phase 3	Hormone Sensitive Prostate Cancer	-	-
MabThera®	Phase 3	Follicular Lymphoma	-	-
MenACWY-CRM	Phase 3	Meningococcal Vaccine	-	-
DA-9501	Phase 3	Sedation	-	-
paclitaxel	Phase 3	Breast Neoplasms	-	-
rLP2086	Phase 3	Healthy	-	-
Investigational Medical Product (IMP) administered in parent study	Phase 3	Osteoarthritis	-	-
VENLAFAXINE	Phase 3	Panic Disorders	-	-
tacrolimus	Phase 3	Kidney Transplantation	-	-
PF-05280586	Phase 3	Rheumatoid Arthritis	-	-
Quadrivalent influenza modRNA vaccine	Phase 3	Influenza, Human	-	-
voxelotor	Phase 3	Sickle Cell Disease	-	-
Standard Ibuprofen	Phase 3	Pain	-	-
23vPS	Phase 3	Vaccines, Pneumococcal Conjugate Vaccine	-	-
Solution Vehicle	Phase 3	Onychomycosis of Toenails	-	-
Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg	Phase 3	Contraception	-	-
Megestrol acetate	Phase 3	Metastatic Breast Cancer	-	-
Lorazepam	Phase 3	Reflex Epilepsy, Photosensitive	-	-
RSVpreF MDV	Phase 3	Respiratory Syncytial Virus (RSV)	-	-
TBE vaccine 0.5 mL	Phase 3	Tick-Borne Encephalitis	-	-
Exubera (inhaled insulin)	Phase 3	Diabetes Mellitus, Type 2	-	-
ibuzatrelvir	Phase 3	COVID-19 Infection	-	-
Inotuzumab ozogamicin	Phase 3	ACUTE LYMPHOBLASTIC LEUKEMIA	-	-
7vPnC	Phase 3	Vaccines, Pneumococcal	-	-
Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)	Phase 3	Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis	-	-
FLAG (fludarabine, cytarabine and G-CSF)	Phase 3	Acute Lymphoblastic Leukemia	-	-
MenABCWY	Phase 3	Meningococcal Vaccine	-	-
PF-06462700	Phase 3	Aplastic Anemia	-	-
Multivalent Group B streptococcus vaccine	Phase 3	Group B Streptococcus Infections	-	-
Infanrix hexa	Phase 3	Healthy	-	-
PF-06651600 Induction Dose	Phase 3	Alopecia Areata	-	-
C.difficile vaccine	Phase 3	Clostridioides Difficile Associated Disease	-	-
Celebrex	Phase 3	Osteoarthritis,Knee	-	-
Abemaciclib	Phase 3	Breast Cancer	-	-
propiverine	Phase 3	Urinary Bladder, Overactive	-	-
ATRA plus 6-MP and MTX	Phase 3	Leukemia, Myelocytic, Acute	-	-
Sirolimus (Rapamune®)	Phase 3	Renal Transplant	-	-
somatrogon	Phase 3	Growth Hormone Deficiency	-	-
ampicillin sodium/sulbactam sodium	Phase 3	Pneumonia, Bacterial	-	-
pantoprazole sodium enteric-coated spheroid suspension	Phase 3	Gastroesophageal Reflux	-	-
Chemotherapy Regimen 1	Phase 3	Advanced Non-Small Cell Lung Cancer	-	-
ALO-02	Phase 3	Chronic Pain	-	-
exemestane (Aromasin)	Phase 3	Breast Neoplasms	-	-
somatropin - GH naïve pediatric cohort	Phase 3	Prader-Willi Syndrome	-	-
Sirolimus (RAPAMUNE)	Phase 3	Graft vs Host Disease	-	-
Meningococcal group C polysaccharide conjugate vaccine	Phase 3	Neisseria Meningitidis	-	-
Donepezil (Aricept)	Phase 3	Alzheimer Disease	-	-
Moxifloxacin	Phase 3	Chronic Bronchitis	-	-
binodenoson	Phase 3	Coronary Artery Disease	-	-
Itraconazole	Phase 3	Antifungal Prophylaxis of Invasive Fungal Infections	-	-
bivalent rLP2086	Phase 3	Meningococcal Infection	-	-
Inhaled human insulin	Phase 3	Diabetes Mellitus, Type 1	-	-
Temozolomide	Phase 3	Glioblastoma	-	-
Hib	Phase 3	Pneumococcal Infections	-	-
Experimental 20-valent pneumococcal conjugate vaccine (20vPnC)	Phase 3	Pneumococcal Disease	-	-
Elotuzumab	Phase 3	Multiple Myeloma	-	-
FDC IBU/APAP 250 mg/500 mg	Phase 3	Pain	-	-
Matching vehicle control	Phase 3	Dermatitis, Atopic	-	-
Ritlecitinib 50 mg	Phase 3	Chronic Spontaneous Urticaria	-	-
Avelumab	Phase 3	Urothelial Cancer	-	-
DVS-233 SR (desvenlafaxine sustained release )	Phase 3	Major Depressive Disorder	-	-
13 valent pneumococcal conjugate vaccine with Polysorbate 80	Phase 3	Vaccines, Pneumococcal	-	-
Meropenem	Phase 3	Complicated Intra-abdominal Infections	-	-
MET097	Phase 3	Obesity	-	-
RSVpreF (Group 1)	Phase 3	RSV	-	-
Imipenem-cilastatin	Phase 3	Skin Infection	-	-
Diclofenac	Phase 3	Spondylitis, Ankylosing	-	-
Pediacel	Phase 3	Vaccines, Pneumococcal	-	-
Pemetrexed/Cisplatin	Phase 3	NSCLC (Non-small Cell Lung Cancer)	-	-
bazedoxifene 20 mg/ conjugated estrogens 0.45 mg	Phase 3	Menopause	-	-
Amoxicillin/clavulinic acid	Phase 3	Bronchitis, Chronic	-	-
desvenlafaxine succinate (DVS) SR	Phase 3	Vasomotor Symptoms	-	-
PF-06823859	Phase 3	Myositis	-	-
Ritlecitinib	Phase 3	Stable Nonsegmental Vitiligo	-	-
Nonacog alfa	Phase 3	Hemophilia B	-	-
Novel Ibuprofen	Phase 3	Pain	-	-
AG-013736	Phase 3	Carcinoma, Pancreatic Ductal	-	-
Epoetin Hospira Arm	Phase 3	Chronic Kidney Disease (CKD)	-	-
Azithromycin/Chloroquine	Phase 3	Malaria, Falciparum	-	-
Imipenem	Phase 3	Bacterial Pneumonia	-	-
marstacimab	Phase 3	Hemophilia A	-	-
Sunitinib	Phase 3	Neuroendocrine Tumors	-	-
Bosutinib	Phase 3	Polycystic Kidney, Autosomal Dominant	-	-
Inhaled Insulin	Phase 3	Asthma	-	-
Rimegepant	Phase 3	Acute Migraine	-	-
Bazedoxifene/Conjugate Estrogens (CE)	Phase 3	Endometrial Hyperplasia	-	-
7-valent Pneumococcal Conjugate Vaccine	Phase 3	Pneumococcal Infection	-	-
Modified Bolus 5-FU/LV with Irinotecan	Phase 3	Colorectal Neoplasms	-	-
varenicline (CP-526,555)	Phase 3	Smoking Cessation	-	-
Tigecycline	Phase 3	Gram-Positive Bacterial Infections	-	-
fesoterodine fumarate	Phase 3	Overactive Bladder	-	-
amoxicillin	Phase 3	Tonsillitis	-	-
SPM 907	Phase 3	Overactive Bladder Syndrome	-	-
Somatropin	Phase 3	Endocrine System Diseases	-	-
Parecoxib Sodium/Valdecoxib	Phase 3	Pain	-	-
Palbociclib	Phase 3	Breast Cancer	-	-
Pregabalin	Phase 3	Epilepsy, Partial	-	-
amoxicillin/clavulanate postassium (Augmentin ES-600)	Phase 3	Acute Otitis Media	-	-
DVS-233	Phase 3	Menopause	-	-
Tisotumab Vedotin	Phase 3	Cervical Cancer	-	-
13-valent pneumococcal conjugate vaccine	Phase 3	Pneumococcal Vaccines	-	-
Sorafenib	Phase 3	Renal Cell Carcinoma	-	-
levonorgestrel/ethinyl estradiol	Phase 3	Menstruation Disturbances	-	-
Ritlecitinib higher dose	Phase 3	Severe Alopecia Areata	-	-
PF-07321332	Phase 3	COVID-19	-	-
AN2690 Topical Solution, 5%	Phase 3	Onychomycosis of Toenails	-	-
AN2728 Topical Ointment, 2%	Phase 3	Dermatitis, Atopic	-	-
Pentavac	Phase 3	Vaccines, Pneumococcal	-	-
Encorafenib	Phase 3	BRAF V600E-mutant Metastatic Colorectal Cancer	-	-
20-valent pneumococcal conjugate vaccine	Phase 3	Pneumococcal Disease	-	-
Talazoparib with enzalutamide	Phase 3	mCRPC	-	-
Group C Meningococcal Polysaccharide-Tetanus Toxoid Conjugate Vaccine (GCMP-TT)	Phase 3	Meningitis, Meningococcal	-	-
Letrozole	Phase 3	Breast Neoplasms	-	-
Genotropin	Phase 3	Idiopathic Short Stature	-	-
oxycodone HCl and naltrexone HCl extended-release capsules	Phase 3	Chronic Noncancer Pain	-	-
Zavegepant	Phase 3	Migraine	-	-
pantoprazole	Phase 3	Gastroesophageal Reflux	-	-
[S,S]-Reboxetine	Phase 3	Fibromyalgia	-	-
PF-06651600	Phase 3	Active Non-segmental Vitiligo	-	-
Taliglucerase alfa	Phase 3	Gaucher Disease	-	-
fluconazole	Phase 3	Tinea Capitis	-	-
PF-06410293	Phase 3	Rheumatoid Arthritis	-	-
linezolid	Phase 3	Febrile Neutropenia	-	-
Group C Meningococcal Polysaccharide-Tetansu Toxoid Conjugate (MenC-TT) vaccine and 7-valent Pneumococcal CRM197-conjugate vaccine (PCV7)	Phase 3	Neisseria Meningitidis (Bacterial Meningitis)	-	-
Desvenlafaxine succinate sustained-release (DVS SR)	Phase 3	Depression	-	-
Epirubicin with Cyclophosphamide, followed by a Taxane	Phase 3	Adenocarcinoma	-	-
Ceftazidime-avibactam	Phase 3	Complicated Intra-abdominal Infection	-	-
talazoparib plus enzalutamide	Phase 3	Prostate Cancer	-	-
Ibuprofen/Caffeine	Phase 3	Pain	-	-
PF-06947386	Phase 3	Complicated Intra-abdominal Infection	-	-
tucatinib	Phase 3	HER2-positive Breast Cancer	-	-
CP-690,550	Phase 3	Crohn's Disease	-	-
Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)	Phase 3	Encephalitis, Tick-borne	-	-
Bococizumab (PF-04950615;RN316)	Phase 3	Hyperlipidemia	-	-
Azithromycin	Phase 3	Community Acquired Pneumonia (CAP)	-	-
ponsegromab	Phase 3	Non-small Cell Lung Cancer	-	-
Dexmedetomidine	Phase 3	Sedation	-	-
DVS-233 SR	Phase 3	Major Depressive Disorder	-	-
Dacomitinib (PF-00299804)	Phase 3	Non-Small Cell Lung Cancer	-	-
Genotropin (PN-180,307) Somatropin	Phase 3	Infant, Small for Gestational Age	-	-
exemestane	Phase 3	Breast Neoplasms	-	-
Erlotinib	Phase 3	Non-small Cell Lung Cancer	-	-
sumanirole	Phase 3	Parkinson Disease	-	-
UK-390,957	Phase 3	Ejaculation	-	-
torcetrapib/atorvastatin	Phase 3	Hyperlipidemia	-	-
RSVpreF	Phase 3	RSV Infection	-	-
disitamab vedotin	Phase 3	Urothelial Carcinoma	-	-
Fesoterodine	Phase 3	Overactive Bladder Syndrome	-	-
Nimenrix	Phase 3	Meningococcal Vaccine	-	-
7-Valent Pneumococcal Conjugate Vaccine (7vPnC)	Phase 3	Healthy Subjects	-	-
Meningococcal vaccine GSK134612	Phase 3	Infections, Meningococcal	-	-
13-valent pneumococcal conjugate vaccine (13vPnC)	Phase 3	Healthy Subjects	-	-
Moroctocog alfa (AF-CC)	Phase 3	Hemophilia A	-	-
lecozotan SR (SRA-333)	Phase 3	Alzheimer Disease	-	-
tanezumab 10 mg	Phase 3	Osteoarthritis	-	-
Desvenlafaxine Succinate Sustained-Release 10mg	Phase 3	Major Depressive Disorder	-	-
olmesartan alone or in combination with hydrochlorothiazide	Phase 3	Essential Hypertension	-	-
7 valent pneumococcal conjugate vaccine	Phase 3	Vaccines, Pneumococcal	-	-
Inhaled human insulin (EXUBERA™)	Phase 3	Diabetes Mellitus, Type 2	-	-
Tolterodine ER	Phase 3	Overactive Bladder	-	-
Fragmin	Phase 3	Diabetic Foot Ulcer	-	-
Tafamidis	Phase 3	Transthyretin (TTR) Amyloid Cardiomyopathy	-	-
Interferon-alfa	Phase 3	Carcinoma, Renal Cell	-	-
tanezumab	Phase 3	Arthritis	-	-
13vPnC	Phase 3	Vaccines, Pneumococcal Conjugate Vaccine	-	-
Rifabutin	Phase 3	Mycoses	-	-
endocrine-modulating drug therapy	Phase 3	Prostate Cancer	-	-
Ibuprofen Sodium	Phase 3	Pain	-	-
ceftazidim-avibactam (CAZ-AVI, experimental product)	Phase 3	Nosocomial Pneumonia (NP)	-	-
Gefitinib	Phase 3	Non-small Cell Lung Cancer With EGFR-Activating Mutations	-	-
Carboplatin	Phase 3	Non-Small-Cell Lung Carcinoma	-	-
leflunomide	Phase 3	Prostate Cancer	-	-
Cyclosporin or tacrolimus	Phase 3	Graft Rejection	-	-
Edotecarin	Phase 3	Breast Neoplasms	-	-
Ceftaroline fosamil	Phase 3	Complicated Skin and Soft Tissue Infection	-	-
Levonorgestrel 90 mg and Ethinyl Estradiol 20 mg	Phase 3	Oral Contraceptive	-	-
Enbrel (etanercept)	Phase 3	Ankylosing Spondylitis	-	-
Zmax	Phase 3	Otitis Media	-	-
Venlafaxine ER	Phase 3	Panic Disorder	-	-
vancomycin with aztreonam	Phase 3	Skin Diseases, Infectious	-	-
ARV-471	Phase 3	Advanced Breast Cancer	-	-
ARV-471 (PF-07850327)	Phase 3	Breast Cancer	-	-
valdecoxib	Phase 3	Pain	-	-
Havrix (HAV)	Phase 3	Meningococcal Vaccine	-	-
NWP09	Phase 3	Attention Deficit Hyperactivity Disorder	-	-
PF-07220060	Phase 3	Liposarcoma	-	-
Rimegepant (PF-07899801)	Phase 3	Acute Treatment of Migraine	-	-
13 valent Pneumococcal Conjugate Vaccine	Phase 3	Pneumococcal Infections	-	-
7vPnc pneumococcal conjugate vaccine	Phase 3	Vaccines, Pneumococcal	-	-
Bifeprunox	Phase 3	Schizophrenia	-	-
Epoetin Hospira	Phase 3	Chronic Renal Failure Requiring Hemodialysis	-	-
Sunitinib malate	Phase 3	Breast Neoplasms	-	-
Ethambutol hydrochloride	Phase 3	Mycobacterium Avium-intracellulare Infection	-	-
ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride ER)	Phase 3	Pain	-	-
ritonavir	Phase 3	COVID-19	-	-
ReFacto AF	Phase 3	Hemophilia A	-	-
binimetinib	Phase 3	MSS	-	-
ropinirole	Phase 3	Parkinson Disease	-	-
Sirolimus	Phase 3	Renal Transplantation	-	-
Desvenlafaxine Succinate Sustained-Release	Phase 3	Major Depressive Disorder	-	-
Gemcitabine	Phase 3	Pancreatic Neoplasms	-	-
Cetuximab	Phase 3	Squamous Cell Carcinoma of the Head and Neck (SCCHN)	-	-
Ceftazidime - Avibactam ( CAZ-AVI)	Phase 3	Complicated Urinary Tract Infection	-	-
Vancomycin	Phase 3	Bacterial Infections	-	-
Dacarbazine	Phase 3	Metastatic or Unresectable Cutaneous Melanoma	-	-
Etanercept	Phase 3	Pulmonary Fibrosis	-	-
Avelumab (MSB0010718C)	Phase 3	Renal Cell Cancer	-	-
Steroids	Phase 3	Kidney Failure	-	-
rFIX	Phase 3	Hemophilia B	-	-
In open-label phase: treatment with tofacitinib	Phase 3	Arthritis Juvenile Idiopathic	-	-
Prednisone	Phase 2	Prostatic Neoplasms	-	-
PF-06826647	Phase 2	Psoriasis	-	-
PF-07038124 ointment 0.01%	Phase 2	Atopic Dermatitis	-	-
rLP2086 and Gardasil	Phase 2	Vaccines	-	-
Bicalutamide	Phase 2	Prostate Cancer	-	-
Sunitinib Malate Continuous Daily Dosing	Phase 2	Carcinoma, Renal Cell	-	-
ARRY-371797, p38 inhibitor, oral	Phase 2	LMNA-Related Dilated Cardiomyopathy	-	-
NXL104/ceftazidime	Phase 2	Complicated Urinary Tract Infection	-	-
PF-07850327, ARV-471, vepdegestrant	Phase 2	Locally Advanced or Metastatic ER+ HER2- Breast Cancer	-	-
CP-690-550	Phase 2	Arthritis, Rheumatoid	-	-
SU-011,248	Phase 2	Kidney Neoplasms	-	-
852A	Phase 2	Melanoma	-	-
PD 0200390	Phase 2	Nonrestorative Sleep	-	-
Multivalent Pneumococcal Vaccine - Formulation 1	Phase 2	Pneumococcal Disease	-	-
0.04 mg/kg CpG 7909	Phase 2	Carcinoma, Breast	-	-
Oxycodone hydrochloride (HCl) extended release (ER), opioid agonist; oral	Phase 2	Osteoarthritis of the Knee	-	-
PF-04360365 10 mg/kg	Phase 2	Alzheimer's Disease	-	-
Combination Agent 1	Phase 2	Advanced/Metastatic Non-Small Cell Lung Cancer	-	-
vabicaserin	Phase 2	Schizophrenia	-	-
axitinib	Phase 2	Carcinoma, Non-Small Cell Lung	-	-
PF-07976016	Phase 2	Obesity	-	-
PF-06291874	Phase 2	Diabetes Mellitus, Type II	-	-
Tanezumab 20 mg IV	Phase 2	Low Back Pain	-	-
60 mg/kg azithromycin ER	Phase 2	Acute Otitis Media	-	-
CP-751, 871	Phase 2	Colorectal Neoplasm	-	-
AN2728 ointment, 2%	Phase 2	Psoriasis	-	-
PF-06882961	Phase 2	Diabetes	-	-
PF-00489791	Phase 2	Diabetic Nephropathies	-	-
PF-610,355	Phase 2	Asthma	-	-
UK-453, 061	Phase 2	HIV-1	-	-
tofacitinib ointment 20 mg/g	Phase 2	Psoriasis Vulgaris	-	-
Combination [RSVpreF+BNTb162b2]	Phase 2	Healthy Participants	-	-
ARRY-502, CRTh2 antagonist; oral	Phase 2	Asthma	-	-
Levonorgestrel	Phase 2	Ovulation	-	-
Formulation A	Phase 2	Respiratory Tract Infections	-	-
Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection	Phase 2	Shingles	-	-
CPG 7909 Injection	Phase 2	Carcinoma, Melanoma	-	-
AN2690, 2.5%	Phase 2	Distal, Subungual Onychomycosis	-	-
PD-0299685	Phase 2	Hot Flashes	-	-
Multivalent	Phase 2	Pneumococcal Infections	-	-
UK0369,003	Phase 2	Impotence	-	-
Filibuvir	Phase 2	Hepatitis	-	-
CP-690,550 Vehicle	Phase 2	Dry Eye Syndromes	-	-
Mylotarg (gemtuzumab ozogamicin) Injection	Phase 2	Acute Myelogenous Leukemia	-	-
AN2728	Phase 2	Psoriasis	-	-
PF-04383119	Phase 2	Cystitis, Interstitial	-	-
PF-04449913	Phase 2	Acute Myeloid Leukemia	-	-
PD 0299685 at 15mg BID	Phase 2	Interstitial Cystitis	-	-
PF-05089771 150 mg	Phase 2	Diabetic Neuropathy, Painful	-	-
PF-04217329	Phase 2	Glaucoma, Open-Angle	-	-
PF-06882961 (Cohorts 1 and 2)	Phase 2	Obesity	-	-
ARRY-438162, MEK inhibitor; oral	Phase 2	Rheumatoid Arthritis	-	-
ACC-001	Phase 2	Alzheimer's Disease	-	-
FOLFIRI (The combination regimen of Irinotecan, l-Leucovorin and 5-Fluorouracil)	Phase 2	Unresectable or Metastatic Colorectal Cancer	-	-
Bazedoxifene	Phase 2	Postmenopausal Osteoporosis	-	-
PF-05221304	Phase 2	Nonalcoholic Fatty Liver Disease	-	-
SKI-606 (Bosutinib)	Phase 2	Chronic Myelogenous Leukemia	-	-
ARRY-520, KSP(Eg5) inhibitor; intravenous	Phase 2	Multiple Myeloma	-	-
ibuprofen	Phase 2	Pain	-	-
Doxycycline	Phase 2	Non Small Cell Lung Cancer (NSCLC)	-	-
FOLFIRI (Irinotecan, leucovorin, 5-fluorouracil [5FU])	Phase 2	Colorectal Neoplasms	-	-
IMA-638	Phase 2	Asthma	-	-
HSP-130	Phase 2	Non-metastatic Breast Cancer	-	-
Tofacitinib ointment 20mg/g	Phase 2	Dermatitis, Atopic	-	-
SCA-136 (200 mg)	Phase 2	Schizophrenia	-	-
Ezetimibe	Phase 2	Hypercholesterolemia	-	-
vepdegestrant	Phase 2	Breast Cancer	-	-
PF-04236921	Phase 2	Crohn's Disease	-	-
TMI-005	Phase 2	Rheumatoid Arthritis	-	-
Crisaborole ointment 2% BID	Phase 2	Dermatitis, Atopic	-	-
MET097 Injection	Phase 2	Obesity in Diabetes	-	-
Influenza ModRNA Vaccine	Phase 2	Influenza, Human	-	-
Group B streptoccous 6-valent polysaccharide conjugate vaccine (GBS6)	Phase 2	Group B Streptococcal Infections	-	-
Tamsulosin	Phase 2	Prostatic Hyperplasia	-	-
Anrukinzumab	Phase 2	Colitis, Ulcerative	-	-
Tofacitinib 2 mg	Phase 2	Ankylosing Spondylitis	-	-
meningococcal B rLP2086 vaccine.	Phase 2	Meningitis, Meningococcal	-	-
PH-797804	Phase 2	Pulmonary Disease, Chronic Obstructive	-	-
PF-06463922	Phase 2	ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC	-	-
IMA-638 is a biologic	Phase 2	Asthma	-	-
CPG 7909	Phase 2	Carcinoma, Non-Small Cell Lung	-	-
Statin	Phase 2	Hypercholesterolemia	-	-
PF-07868489	Phase 2	Pulmonary Arterial Hypertension	-	-
PF-06865571	Phase 2	Nonalcoholic Steatohepatitis	-	-
PF-04136309	Phase 2	Osteoarthritis, Knee	-	-
Vaccine Candidate #1	Phase 2	Healthy Adults	-	-
exemestane (Aromasin®)	Phase 2	Breast Neoplasms	-	-
SS-RBX	Phase 2	Urinary Incontinence, Stress	-	-
Peg-Intron	Phase 2	Hepatitis C	-	-
bapineuzumab	Phase 2	Alzheimer Disease	-	-
PF-06700841	Phase 2	Psoriatic Arthritis	-	-
Filanesib, KSP (Eg5) inhibitor; intravenous	Phase 2	Advanced Multiple Myeloma	-	-
Enfortumab Vedotin	Phase 2	Urothelial Cancer	-	-
Elranatamab (PF-06863135)	Phase 2	Multiple Myeloma	-	-
ACC-001 3 μg/ QS-21 50 μg	Phase 2	Alzheimer's Disease	-	-
Anti-Beta Interferon (PF-06823859)	Phase 2	Dermatomyositis	-	-
RV521	Phase 2	Respiratory Syncytial Virus Infections	-	-
azithromycin immediate release (Zithromax)	Phase 2	Pharmacokinetics	-	-
PF-07220060 + PF-07104091 combination dose escalation	Phase 2	Breast Cancer	-	-
EXC 001	Phase 2	Scar Prevention	-	-
SAM-531	Phase 2	Alzheimer Disease	-	-
Irinotecan plus capecitabine	Phase 2	Carcinoma, Hepatocellular	-	-
PF-00734200 30 mg QD	Phase 2	Diabetes Mellitus, Type 2	-	-
Tasocitinib plus Methotrexate	Phase 2	Rheumatoid Arthritis	-	-
Tolterodine & Pregabalin	Phase 2	Overactive Bladder	-	-
CP-778,875	Phase 2	Dyslipidemia	-	-
PF-00592379	Phase 2	Impotence	-	-
CP-533, 536	Phase 2	Tibial Fractures	-	-
SBI-087	Phase 2	Active Rheumatoid Arthritis	-	-
sulopenem and PF-03709270	Phase 2	Pneumonia, Bacterial	-	-
PF-04494700 - Low Dose Arm	Phase 2	Alzheimer Disease	-	-
PF-04634817	Phase 2	Diabetic Nephropathy	-	-
Allegra	Phase 2	Allergic Rhinitis	-	-
rhBMP-2/CPM	Phase 2	Fractures	-	-
ACC-001 + QS-21	Phase 2	Alzheimer Disease	-	-
CE-224,535	Phase 2	Arthritis, Rheumatoid	-	-
BNT162b2 (Omi XBB.1.5)/RIV	Phase 2	Influenza, Human	-	-
AG-013726	Phase 2	Colorectal Neoplasms	-	-
MultiStem low dose	Phase 2	Colitis, Ulcerative	-	-
cytarabine.	Phase 2	Acute Myeloid Leukemia	-	-
Celecoxib + Exemestane	Phase 2	Breast Neoplasms	-	-
PELITREXOL/AG-2037	Phase 2	Colorectal Neoplasms	-	-
EXC 001 (currently called PF-06473871)	Phase 2	Reduction in Severity of Skin Scarring	-	-
SPK-9001	Phase 2	Hemophilia B	-	-
CP-866,087	Phase 2	Alcoholism	-	-
rhBMP-2/CPM injection and bisphosphonates, calcium, and vitamin D (oral bisphosphonate therapy)	Phase 2	Osteoporosis	-	-
ceftazidime/NXL104 + metronidazole	Phase 2	Complicated Intra-abdominal Infections	-	-
CCI-779	Phase 2	Multiple Sclerosis, Relapsing-Remitting	-	-
ARRY-371797, p38 inhibitor; oral	Phase 2	LMNA-Related Dilated Cardiomyopathy	-	-
sunitinib malate dose escalation	Phase 2	Gastrointestinal Stromal Tumors	-	-
CP-751,871	Phase 2	Prostatic Neoplasms	-	-
CPG10101	Phase 2	Hepatitis, Chronic Active	-	-
PF-06372865	Phase 2	Chronic Low Back Pain	-	-
Carfilzomib, proteasome inhibitor; intravenous	Phase 2	Advanced Multiple Myeloma	-	-
RSV Vaccine	Phase 2	Respiratory Tract Infection	-	-
PF-06835375	Phase 2	Primary Immune Thrombocytopenia	-	-
Torisel	Phase 2	Adenocarcinoma	-	-
PF-06835919	Phase 2	Non-alcoholic Steatohepatitis	-	-
lecozotan SR	Phase 2	Alzheimer Disease	-	-
dalteparin	Phase 2	Venous Thromboembolism	-	-
Tygacil	Phase 2	Bacterial Infections	-	-
PG4	Phase 2	Pneumococcal Disease	-	-
BYL719	Phase 2	Colorectal Cancer	-	-
Dacomitinib	Phase 2	Non-small Cell Lung Cancer	-	-
PF-00232798	Phase 2	HIV	-	-
SB-525 (PF-07055480)	Phase 2	Hemophilia A	-	-
PF-07817883	Phase 2	SARS-CoV-2 Infection	-	-
MYO-029	Phase 2	Becker Muscular Dystrophy	-	-
C. difficile vaccine (previously studied formulation).	Phase 2	Clostridoides Difficile Associated Disease	-	-
Kaletra	Phase 2	HIV Infections	-	-
SRA-333	Phase 2	Alzheimer's Disease	-	-
CI-1040	Phase 2	Colorectal Neoplasms	-	-
PF-04171327 10 mg	Phase 2	Rheumatoid Arthritis	-	-
(Part C) MET097	Phase 2	Obesity and Overweight	-	-
PF-3512676 + Erlotinib	Phase 2	Carcinoma, Non-Small-Cell Lung	-	-
Low Dose PF-07328948	Phase 2	Heart Failure	-	-
SU011248 (sunitinib)	Phase 2	Carcinoma, Renal Cell Metastasis	-	-
PF-04950615 (RN316)	Phase 2	Hypercholesterolemia	-	-
PF-00299804	Phase 2	Carcinoma, Non Small Cell Lung	-	-
Rapamune® (Sirolimus)	Phase 2	Kidney Transplantation	-	-
PF-04360365 0.1 mg/kg	Phase 2	Alzheimer's Disease	-	-
Sunitinib malate (SU011248)	Phase 2	Gastrointestinal Stromal Tumors	-	-
SD-6010	Phase 2	Osteoarthritis	-	-
CP-690,550 Ointment 1	Phase 2	Psoriasis	-	-
AN2690	Phase 2	Onychomycosis	-	-
PF-04383119 (RN624)	Phase 2	Low Back Pain	-	-
PF-07104091 monotherapy dose escalation	Phase 2	Small Cell Lung Cancer	-	-
NR2B NMDA Antagonist CP-101,606 (traxoprodil)	Phase 2	Parkinson's Disease	-	-
NMDA Antagonist, CP-101,606 (traxoprodil)	Phase 2	Depressive Disorder, Major	-	-
PF-04937319 10 mg	Phase 2	Diabetes Mellitus, Type 2	-	-
Vaccine	Phase 2	Meningococcal Vaccine	-	-
MET233 and MET097	Phase 2	Obesity and Obesity-related Medical Conditions	-	-
PF-08049820	Phase 2	Atopic Dermatitis	-	-
Letrozole / Temsirolimus (CCI-779)	Phase 2	Breast Neoplasms	-	-
PF-04383119 (tanezumab)	Phase 2	Osteoarthritis, Knee	-	-
Sunitinib (SU011248)	Phase 2	Liver Neoplasms	-	-
AN2728 Ointment Vehicle	Phase 2	Psoriasis	-	-
Combination 1	Phase 2	Carcinoma, Renal Cell	-	-
Ceftazidime -avibactam	Phase 2	Complicated Urinary Tract Infections	-	-
Vupanorsen	Phase 2	Dyslipidemias	-	-
tacedinaline	Phase 2	Pancreatic Cancer	-	-
150 mg PF-04991532	Phase 2	Diabetes, Type 2	-	-
inotuzumab ozogamicin (CMC-544)	Phase 2	Lymphoma, B-Cell	-	-
AN2898 ointment, 1%	Phase 2	Dermatitis, Atopic	-	-
Samuraciclib	Phase 2	Breast Cancer	-	-
UK-453,061	Phase 2	HIV-1	-	-
CE-326,597 100 mg QD	Phase 2	Weight Management	-	-
CI-1033	Phase 2	Breast Neoplasms	-	-
pregabalin/PF-00489791	Phase 2	Postherpetic Neuralgia	-	-
PF-06823859 low	Phase 2	Dermatomyositis	-	-
PF-03654746	Phase 2	Excessive Daytime Sleepiness	-	-
PF-00217830	Phase 2	Schizophrenia	-	-
EKB-569	Phase 2	Colorectal Neoplasms	-	-
PF-04494700 (TTP488)	Phase 2	Diabetic Nephropathy	-	-
CP-690,550 + methotrexate	Phase 2	Rheumatoid Arthritis	-	-
PF-00446687	Phase 2	Erectile Dysfunction	-	-
Repevax	Phase 2	Meningococcal Vaccine	-	-
ERB-041	Phase 2	Endometriosis	-	-
CI 1033	Phase 2	Lung Neoplasms	-	-
AG-013736 (Axitinib)	Phase 2	Acute Myeloid Leukemia (AML)	-	-
ILV-094	Phase 2	Rheumatoid Arthritis	-	-
LEE011	Phase 2	Locally Advanced or Metastatic NRAS Mutant Melanoma	-	-
Open	Phase 2	Chronic Kidney Disease	-	-
QS-21	Phase 2	Alzheimer Disease	-	-
PBO	Phase 2	Hypercholesterolemia	-	-
PF-04494700	Phase 2	Alzheimer's Disease	-	-
Gefitinib + Sunitinib	Phase 2	Carcinoma, Renal Cell	-	-
PF-06838435 (formerly SPK-9001)	Phase 2	Hemophilia B	-	-
CP-690,550 Eye drops	Phase 2	Dry Eye Syndromes	-	-
Zithromax (azithromycin) 500mg tablets	Phase 2	Sinusitis	-	-
Tofimilast	Phase 2	Asthma	-	-
Vascular Endothelial Growth Factor Receptor [VEGFR] and Platelet-Derived Growth Factor Receptor [PDGFR] inhibitor	Phase 2	Kidney Neoplasms	-	-
PF-00734200 10 mg QD	Phase 2	Diabetes Mellitus, Type 2	-	-
Tick-borne Encephalitis Vaccine	Phase 2	Tick-borne Encephalitis	-	-
PF-02545920	Phase 2	Huntington's Disease	-	-
Sumatriptan	Phase 2	Migraine	-	-
25 mg PF-04991532	Phase 2	Diabetes Mellitus, Type 2	-	-
RN624	Phase 2	Neuralgia, Postherpetic	-	-
Ibuprofen/acetaminophen	Phase 2	Pain	-	-
PF-04937319 - 3mg	Phase 2	Type 2 Diabetes Mellitus	-	-
PD-217,014	Phase 2	Irritable Bowel Syndrome	-	-
MAC-321	Phase 2	Colorectal Neoplasms	-	-
AN2690, 5%	Phase 2	Distal, Subungual Onychomycosis	-	-
PF-06650833	Phase 2	Acne Inversa	-	-
Axitinib [AG-013736]	Phase 2	Melanoma	-	-
Dexmedetomidine, midazolam; fentanyl	Phase 2	Intubated and Mechanically Ventilated Pediatric Subjects	-	-
CP- 690 550	Phase 2	Ulcerative Colitis	-	-
BGJ398	Phase 2	Melanoma	-	-
PF-04191834	Phase 2	Asthma	-	-
PF-04171327	Phase 2	Rheumatoid Arthritis	-	-
CP-526,555 (varenicline)	Phase 2	Smoking Cessation	-	-
Risperidone	Phase 2	Schizophrenia	-	-
PF-05089771	Phase 2	Postoperative Dental Pain	-	-
mPnC candidate	Phase 2	Healthy Participants	-	-
Anti-NGF AB	Phase 2	Neoplasms	-	-
MET233	Phase 2	Obesity and Overweight	-	-
mIRV	Phase 2	Influenza, Human	-	-
active comparator	Phase 2	Pulmonary Disease, Chronic Obstructive	-	-
PF-00610355	Phase 2	Pulmonary Disease, Chronic Obstructive	-	-
Leuprolide	Phase 2	Prostate Cancer	-	-
Capecitabine	Phase 2	Breast Cancer	-	-
Naproxen + PH-797804	Phase 2	Osteoarthritis	-	-
Atomoxetine	Phase 2	Attention Deficit Disorder With Hyperactivity	-	-
Methotrexate plus ERB-041 for 12 weeks	Phase 2	Rheumatoid Arthritis	-	-
RN624 (PF-04383119)	Phase 2	Osteoarthritis	-	-
Elranatamab + Nirogacestat	Phase 2	Multiple Myeloma	-	-
MRE0094	Phase 2	Foot Ulcer, Diabetic	-	-
ALO-01	Phase 2	Healthy	-	-
cyclophosphamide	Phase 2	Peripheral T-cell Lymphoma	-	-
Capravirine	Phase 2	Human Immunodeficiency Virus	-	-
Bivalent rLP2086 Vaccine	Phase 2	MENINGOCOCCAL INFECTION	-	-
AN2690 Solution, 5.0%	Phase 2	Onychomycosis	-	-
PF-05221304 Monotherapy	Phase 2	Non-Alcoholic Fatty Liver Disease (NAFLD)	-	-
PF-00868554	Phase 2	Hepatitis C	-	-
Sitexsentin sodium	Phase 2	Diastolic Heart Failure	-	-
Tisotumab vedotin (HuMax-TF-ADC)	Phase 2	Ovary Cancer	-	-
PF-04457845	Phase 2	Osteoarthritis, Knee	-	-
PF-07275315	Phase 2	Asthma	-	-
Part A: ATM-AVI Single Dose, Cohorts 1-4	Phase 2	Gram-negative Bacterial Infection	-	-
Meningococcal C	Phase 2	Meningitis, Meningococcal	-	-
PD 0348292	Phase 2	Venous Thrombosis	-	-
PF-06835919 Low Dose	Phase 2	Non-alcoholic Fatty Liver Disease	-	-
PF-03654764	Phase 2	Allergic Rhinitis	-	-
Staphylococcus aureus 4-antigen vaccine	Phase 2	Staphylococcal Infections	-	-
Bortezomib	Phase 2	Multiple Myeloma	-	-
Sertraline and Elzasonan Combination	Phase 2	Depressive Disorder, Major	-	-
Investigational drug	Phase 2	Carcinoma, Non-Small-Cell Lung	-	-
SU011248 capsule	Phase 2	Carcinoma, Renal Cell	-	-
CP-547,632	Phase 2	Ovarian Neoplasms	-	-
PF-07264660	Phase 2	Atopic Dermatitis	-	-
PF-3512676	Phase 2	Lymphoma, T-Cell, Cutaneous	-	-
BAT	Phase 2	Gram-negative Bacterial Infections	-	-
AN2728 Topical Ointment, 2% QD	Phase 2	Dermatitis, Atopic	-	-
Tanezumab 10 mg IV	Phase 2	Neoplasm Metastasis	-	-
PF-07220060 CDK4 inhibitor	Phase 2	Advanced or Metastatic Breast Cancer	-	-
PF-07038124 ointment	Phase 2	Atopic Dermatitis	-	-
Crisaborole ointment 2%	Phase 2	Atopic Dermatitis	-	-
Pediatric HAV vaccine	Phase 2	Meningococcal B Disease	-	-
PF-06700841 15 mg	Phase 2	Systemic Lupus Erythematosus	-	-
Ponezumab	Phase 2	Cerebral Amyloid Angiopathy	-	-
Esreboxetine	Phase 2	Fibromyalgia	-	-
UK-369,003	Phase 2	Prostatic Hyperplasia	-	-
PF-04447943	Phase 2	Alzheimer's Disease	-	-
ACC-001(3µg) + QS21	Phase 2	Alzheimer Disease	-	-
PD 0332991	Phase 2	Breast Cancer	-	-
maplirpacept (PF-07901801)	Phase 2	Diffuse Large B-Cell Lymphoma	-	-
15-valent pneumococcal conjugate vaccine (PCV15)	Phase 2	Pneumococcal Disease	-	-
Celecoxib, COX-2 inhibitor; oral	Phase 2	Dental Pain	-	-
PF-04236921 SC injection	Phase 2	Crohn's Disease	-	-
SU014813	Phase 2	Breast Neoplasms	-	-
meningococcal B rLP2086 vaccine candidate	Phase 2	Meningitis, Meningococcal	-	-
Tdap	Phase 2	Pneumococcal Infections	-	-
rLP2086 + MCV4 + Tdap	Phase 2	Vaccines	-	-
Recombinant Human Interleukin-11 (rhIL-11)	Phase 2	Crohn Disease	-	-
sitaxsentan (Thelin)	Phase 2	Cardiac Surgery Subjects	-	-
(CP-6890,550) Tofacitinib	Phase 2	Plaque Psoriasis	-	-
PF-06473871	Phase 2	Reduction of Hypertrophic Skin Scarring	-	-
Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)	Phase 2	Depression	-	-

Renal Transplantation

1 drug in this indication

Major Depressive Disorder

1 drug in this indication

Diabetes Mellitus

1 drug in this indication

Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)

Regulatory Approvals

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

PFIZER

Market Overview

PFE News

Catalyst Timeline

Multivalent Pneumococcal Vaccine - Formulation 1 Phase 2 Results Expected

Pipeline & FDA Submissions

Competitive Positions

AI Predictions & Institutional Flow

Market Intelligence

Regulatory Approvals